The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 29, 2022

Filed:

Mar. 13, 2014
Applicant:

The United States of America, As Represented BY the Secretary, Dept. of Health and Human Services, Bethesda, MD (US);

Inventors:

David D. Roberts, Bethesda, MD (US);

David R. Soto Pantoja, Rockville, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/713 (2006.01); A61K 31/704 (2006.01); A61K 31/437 (2006.01); A61P 39/00 (2006.01); A61K 31/351 (2006.01); A61P 35/00 (2006.01); A61K 31/52 (2006.01); A61K 31/137 (2006.01); A61K 31/365 (2006.01); A61K 31/65 (2006.01); A61K 31/706 (2006.01); A61K 39/395 (2006.01); A61K 31/711 (2006.01); A61K 31/7064 (2006.01); A61K 31/505 (2006.01); A61K 31/712 (2006.01); C07K 16/28 (2006.01); A61K 31/787 (2006.01); A61K 31/513 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/713 (2013.01); A61K 31/137 (2013.01); A61K 31/351 (2013.01); A61K 31/365 (2013.01); A61K 31/437 (2013.01); A61K 31/505 (2013.01); A61K 31/513 (2013.01); A61K 31/52 (2013.01); A61K 31/65 (2013.01); A61K 31/704 (2013.01); A61K 31/706 (2013.01); A61K 31/7064 (2013.01); A61K 31/711 (2013.01); A61K 31/712 (2013.01); A61K 31/787 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 39/00 (2018.01); C07K 16/2803 (2013.01);
Abstract

Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.


Find Patent Forward Citations

Loading…